Giuseppe Leone

Publications (604) View all

• Article: Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.

  M T Voso, E Fabiani, L Fianchi, G Falconi, M Criscuolo, R Santangelo, P Chiusolo, S Betti, F D'Alo, S Hohaus, V De Stefano, G Leone
  Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 09/2012; · 8.30 Impact Factor
• Article: High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

  Luana Fianchi, Marianna Criscuolo, Massimo Breccia, Luca Maurillo, Flavia Salvi, Pellegrino Musto, Giovanna Mansueto, Gianluca Gaidano, Carlo Finelli, Antonietta Aloe-Spiriti, Valeria Santini, Mariangelo Greco, Stefan Hohaus, Giuseppe Leone, Maria Teresa Voso
  Leukemia & lymphoma 08/2012; · 2.40 Impact Factor
• Source

  Available from: Elisabetta Metafuni

  Article: The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.

  Patrizia Chiusolo, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Nicola Piccirillo, Daniela De Ritis, Sara Marietti, Sorà Federica, Luca Laurenti, Luana Fianchi, Stefan Hohaus, Leone Giuseppe, Simona Sica
  [show abstract] [hide abstract]
  ABSTRACT: In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue. We performed the analysis of these polymorphisms on genomic DNA with RFLP-PCR. Patients carrying MTHFR A1298C variant showed decreased hepatic and hematological toxicity (P = 0.03). Overall survival (OS) and progression-free survival (PFS) between homozygous wild-type and variant patients for the RFC1 G(80)A were significantly different (P = 0.035 and P = 0.02, respectively). A significant correlation between hematological toxicity and age (P = 0.003) was observed. There was no significant influence of MTHFR C677T genotype on toxicity, OS and PFS. Leucovorin rescue given after high-dose MTX probably accounts for the lack of influence of C677T polymorphism. To better define a role of RFC1 polymorphism on patients outcome, it would be worthwhile to perform a study on intracellular MTX level and RFC1 substrate binding affinities in different genotypes.
  Cancer Chemotherapy and Pharmacology 03/2012; 69(3):691-6. · 2.83 Impact Factor
• Article: Caspofungin for the treatment of candidaemia in patients with haematological malignancies.

  L Pagano, L Fianchi, R Fanci, A Candoni, M Caira, B Posteraro, M Morselli, C G Valentini, G Farina, M E Mitra, M Offidani, M Sanguinetti, M E Tosti, A Nosari, G Leone, P Viale
  [show abstract] [hide abstract]
  ABSTRACT: This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
  Clinical Microbiology and Infection 06/2009; 16(3):298-301. · 4.54 Impact Factor
• Article: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.

  S Hohaus, M Giachelia, G Massini, G Mansueto, B Vannata, V Bozzoli, M Criscuolo, F D'Alò, M Martini, L M Larocca, M T Voso, G Leone
  [show abstract] [hide abstract]
  ABSTRACT: Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases. Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene. Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all). Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively). In HL, histological signs of necrosis and grade 2 type of nodular sclerosis were associated with increased plasma DNA. Elevated plasma DNA levels were associated with an inferior failure-free survival in patients with HL (P = 0.01) and DLBCL (P = 0.03). Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.
  Annals of Oncology 05/2009; 20(8):1408-13. · 6.43 Impact Factor